Biomarker-Positive Cohort Identification Automation Workflow

Manual review of lab, pathology, and genomic reports for biomarker status is a sequential, expert-dependent bottleneck. A custom multi-agent workflow automates ingestion, parsing, and interpretation, turning weeks of chart review into hours of automated processing. The savings come from parallelized data handling, NLP-based entity extraction from unstructured reports, and immediate flagging of positive results against protocol criteria.

Manual screening is prone to oversight and inconsistency, especially with complex biomarker logic across multiple data sources. An automated workflow applies rules uniformly, checks temporal validity of lab results, and cross-references genomic variants with curated knowledge bases. This reduces costly screen failures at the site by ensuring only patients who truly meet the biomarker criteria are pre-identified, protecting trial budgets and timelines.

The business upside isn't just speed—it's enabling trials that were previously operationally infeasible. Finding NTRK-fusion or ultra-rare genotype patients across a network requires querying millions of records. A custom workflow with federated querying and privacy-preserving record linkage (PPRL) makes this systematic, turning a needle-in-a-haystack search into a repeatable, scalable process that directly supports pipeline valuation and first-to-market goals.

The operational cost of manual screening involves significant FTE time from clinical coordinators, data managers, and medical monitors. Automating the initial identification and ranking shifts this labor to exception handling and validation. The savings compound through reduced site burden, lower data management queries, and more efficient use of central lab and sequencing budgets by pre-qualifying patients.

Manual processes lack transparency, creating regulatory risk. A custom workflow embeds governance by design: each eligibility flag is accompanied by an evidence trail (source report snippets, lab values, decision logic). Automated audit logs track every data access and decision, generating inspection-ready packages on demand. This mitigates compliance risk and builds sponsor/CRO confidence in the automated output.

Impact depends on seamless integration, not a standalone tool. The workflow's value is realized through agents that connect to Epic/Cerner EHRs, lab information systems (LIS), genomic data platforms (e.g., Pierian, Seven Bridges), and EDC/CTMS like Veeva or Medidata. The architecture uses orchestration frameworks (LangGraph, Prefect) to manage state, handle exceptions, and route candidate lists with physician review flags into existing clinical operations workflows.

This agent orchestrates the secure, continuous ingestion of raw data from disparate sources: HL7 feeds from lab information systems (LIS), PDF pathology reports from Epic or Cerner, and FASTQ/VCF files from genomic sequencing pipelines. It normalizes biomarker nomenclatures (e.g., mapping 'PD-L1 IHC 22C3' to a standard code), handles missing fields, and outputs a unified, temporal patient record. Without this component, data scientists spend 60-80% of their time on manual wrangling instead of analysis.

The core decision layer where domain-specific agents apply protocol rules. A Genomic Variant Agent parses VCFs to call actionable mutations (e.g., EGFR L858R) against curated knowledge bases like ClinVar. A Pathology Report Agent uses NLP to extract positive/negative status and tumor proportion scores from unstructured notes. Logic is encoded as executable rules (e.g., IF PD-L1 TPS >= 50% THEN status = positive) enabling transparent, auditable decisions that replace error-prone manual interpretation.

This component, often built with LangGraph or Temporal, sequences the workflow: trigger ingestion, await agent results, apply inclusion/exclusion logic, and compile a candidate list. It scores patients based on biomarker match confidence, temporal recency of tests, and completeness of records. The output is a prioritized, de-duplicated cohort list ready for review, turning a multi-week manual compilation into a daily automated report.

Automation must preserve human oversight. This layer integrates with clinical workstations (e.g., Epic Hyperspace) to present flagged patients with AI-generated rationales and source evidence. It manages a review queue, routes ambiguous cases (e.g., conflicting test results) to the appropriate specialist, and logs all approvals/rejections with timestamps for audit. This controlled handoff is critical for clinician trust and regulatory acceptance.

A non-negotiable component for life sciences. This agent immutably logs every data access, processing step, decision rationale, and user action against patient and protocol IDs. It automatically redacts PHI for downstream use and can generate inspection-ready packages for FDA or EMA audits on demand. This turns compliance from a manual, retrospective scramble into a built-in, continuous process.

The practical implementation plane. This involves containerized agents (Docker/K8s) for scalability, API gateways for connecting to EDC (Medidata Rave, Veeva EDC), CTMS, and EHR systems, and a message queue (RabbitMQ, Kafka) to handle streaming lab results. A pilot deployment typically uses a synthetic data sandbox first, then a phased rollout to live Epic/Cerner environments with strict feature flags and rollback procedures.